Genmab A (GMAB) Cost of Revenue (2024 - 2026)

Genmab A has reported Cost of Revenue for 3 years, with the latest figure at $65.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 54.76% year-over-year to $65.0 million; the trailing twelve-month figure through Mar 2026 stood at $222.0 million (up 62.04% YoY), and the FY2025 full-year result was $238.0 million, up 66.43% from the prior year.
• Cost of Revenue for Q1 2026 stood at $65.0 million, up from $58.0 million in the prior quarter.
• The five-year high for Cost of Revenue was $65.0 million in Q1 2026, with the low at $27.0 million in Q1 2024.
• Historically, Cost of Revenue has averaged $45.3 million across 3 years, with a median of $42.0 million in 2025.
• The largest YoY upside for Cost of Revenue was 103.57% in 2025 against a maximum downside of 45.0% in 2025.
• Genmab A's Cost of Revenue stood at $40.0 million in 2024, then jumped by 45.0% to $58.0 million in 2025, then advanced by 12.07% to $65.0 million in 2026.
• The last three Cost of Revenue figures came in at $65.0 million (Q1 2026), $58.0 million (Q3 2025), and $57.0 million (Q2 2025), per Business Quant data.